Freenome Raises $300M In Series D Financing To Advance Multiomics Platform For Early Cancer Detection

Dec 07, 2021•about 4 years ago

Amount Raised

$300 Million

Round Type

series d

San FranciscoBiotechnologyScience And EngineeringHealth Care

Description

Freenome, a privately held biotech company, today announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.

Company Information

Company

Freenome Holdings

Location

San Francisco, California, United States

About

Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Freenome Raises $300M In Series D Financing To Advance Multiomics Platform For Early Cancer Detection

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information